Watchlist Price Alert

Zura Bio Limited (ZURA)

NASDAQ: ZURA · Real-Time Price · USD

1.01

-0.01 (-0.98%)

At close: May 30, 2025, 3:59 PM

1.04

2.46%

After-hours: May 30, 2025, 05:02 PM EDT

-0.98% (1D)

Bid	0.74
Market Cap	62.8M
Revenue (ttm)	2K
Net Income (ttm)	-64.44M
EPS (ttm)	-0.79
PE Ratio (ttm)	-1.28
Forward PE	-1.34
Analyst	Buy

Ask	1.28
Volume	199,783
Avg. Volume (20D)	400,190
Open	1.02
Previous Close	1.02
Day's Range	0.99 - 1.04
52-Week Range	0.97 - 5.50
Beta	0.04

About ZURA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ZURA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ZURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-10.07%

Zura Bio shares are trading lower after the compan... Unlock content with Pro Subscription

News

5 days ago · businesswire.com

Zura Bio to Present at the Jefferies Global Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway anti...

1 week ago · businesswire.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.

3 weeks ago · businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

2 months ago · businesswire.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway anti...